•   
  •   

US News Vaccine against Covid-19: the clinical trial of Johnson & Johnson will resume

15:25  24 october  2020
15:25  24 october  2020 Source:   rfi.fr

Against Covid-19, the role of Omega 3 at the heart of a study by Rennes University Hospital

 Against Covid-19, the role of Omega 3 at the heart of a study by Rennes University Hospital © Joël Le Gall, Archives Ouest-France Omega 3s are naturally present in the seeds of lupine, flax, rapeseed, soybean, bean A study on the preventive role of Omega 3 against Covid-19, coordinated by the Rennes University Hospital, should start in early 2021. It should show the impact of Omega 3 on acute respiratory distress syndrome (ARDS) , the most serious pathology caused by Covid-19.

The Johnson & Johnson coronavirus vaccine trial , paused earlier this month Rules around clinical trials and patient privacy usually restrict details from being released, but the tremendous scrutiny of In the Johnson & Johnson trial , which was paused on Oct. 12, a man who received a vaccination

© Johnson & Johnson COVID - 19 vaccine vials. On Friday, both AstraZeneca and Johnson & Johnson announced that their coronavirus vaccine trials are set to resume in the U.S. after hitting pause when volunteers became sick.

Doses du vaccin développé par le laboratoire Johnson & Johnson. Actuellement en phase 3, l'essai clinique de ce candidat vaccin contre le Covid-19 doit reprendre. © Cheryl Gerber / Johnson & Johnson via AP Doses of the vaccine developed by the Johnson & Johnson laboratory. Currently in phase 3, the clinical trial of this candidate vaccine against Covid-19 must resume.

He had been interrupted a few days ago. The clinical trial of the candidate vaccine from the American laboratory Johnson & Johnson is expected to resume shortly. Paused following a "serious medical event" in a patient, the company indeed announces that it has found no element implicating the vaccine.

Almost two weeks after its interruption, the recruitment campaign for the phase 3 clinical trial of the Johnson & Johnson vaccine candidate is expected to resume in a few days. The American firm announces in fact that it has found "no evidence" that its vaccine was responsible for an adverse event in one of the volunteers.

Pfizer is aiming for emergency approval for corona vaccine in November

 Pfizer is aiming for emergency approval for corona vaccine in November Frankfurt (Reuters) - The US pharmaceutical company Pfizer is aiming for an application for approval at the end of November if the study results for the corona vaccine developed together with Mainz-based Biontech are positive.

Johnson & Johnson halted clinical trials of its Covid - 19 vaccine after a participant fell ill, the second time that a front-runner developer has paused “We are committed to providing transparent updates throughout the clinical development process of our vaccine candidate,” J&J said in a statement.

Johnson & Johnson Inc. said Friday that it will resume enrolling U.S. participants in a late-stage clinical trial for its experimental COVID - 19 vaccine “Discussions with other regulators around the world to resume the clinical trial program are progressing,” J&J said in a statement.

A total of 60,000 people are to take part in this trial. The other trial set to resume in the United States is the one developed jointly by the AstraZeneca laboratory and the University of Oxford. Interrupted in September for similar reasons, the enrollment of patients had however recommenced a few days later in the world, except in the United States, the only country where the authorities had maintained this suspension until a green light given this Friday.

Two more advanced candidates

These two vaccine candidates are among the most advanced in their development. They are ten in total to have entered phase 3 of clinical trials, the last before the vaccine is marketed. Two other American laboratories, Pfizer and Moderna , are also planning to request marketing authorization from the American health authorities towards the end of November.

These advances give hope that at least one of them will be available by the end of the year.

Virus: Europe tightens its arsenal of restrictions, more than 10,000 dead in Germany .
© Provided by Le Point Several countries of Europe of the East impose new restrictions on Saturday in the wake of the rest of the continent, where the Covid-19 epidemic has now killed more than 10,000 people in Germany and has infected more than a million in France . The restrictions have also caused clashes in Italy , in Naples, between the police and hundreds of young people protesting against the curfew decreed Friday evening in the region of this city.

usr: 0
This is interesting!